MORRISVILLE, N.C.,—April 10, 2012—TearScience®, Inc., a privately-held medical device company, today announced that for the first time live LipiFlow® thermal pulsation treatments will be performed at its exhibit booth #2067 at the ASCRS•ASOA Symposium and Congress. The symposium and congress will be held at McCormick Place West in Chicago, Illinois from April 20-24, 2012. The live treatments will be performed by Parag Majmudar, MD of Chicago Cornea Consultants. LipiFlow® is designed to treat a primary cause of evaporative dry eye disease, obstructed Meibomian glands. The treatment uses precisely controlled heat and pressure applied to the eyelids to unblock obstructed Meibomian glands during a 12-minute procedure. LipiFlow® allows the Meibomian glands to resume their natural production of lipids needed for a healthy tear film. TearScience received FDA clearance on its second generation LipiFlow® treatment device on December 23, 2011.
Additionally, TearScience will host in-booth presentations by leading physicians who will cover the clinical aspects of LipiFlow® and how the treatment can be implemented successfully into an eye care practice. For a schedule of live LipiFlow treatments and physician presentations, visit TearScience’s ASCRS Web page.
TearScience will host an ASCRS-sponsored Corporate Morning meeting on Saturday, April 21, 2012 where attendees can learn about the latest advances in treating Meibomian Gland Dysfunction (MGD) with LipiFlow®. The panel discussion will be moderated by John A. Hovanesian, MD. The panelists include Alan Carlson, MD, Sheldon Herzig, MD, Jay McDonald II, MD, Parag Majmudar, MD and Cherry Tabb, CEO of Herzig Eye Institute. To register for this event, visit the EyeWorld Education Web page.
TearScience will also be an exhibitor at Cornea Day (Table Top Display #24), to be held on Friday, April 20, 2012, at McCormick Place West from 7:30 a.m. – 4:00 p.m.
About TearScience, Inc.
Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical improvement in the treatment of evaporative dry eye. Of the more than 100 million dry eye sufferers worldwide, approximately 86 percent have evaporative dry eye, which is caused by Meibomian Gland Dysfunction (MGD) and a lipid deficiency of the eye’s natural tear film. The Tear Film and Ocular Surface Society (TFOS) workshop, involving two years of work by 50 leading experts from around the world, concluded that MGD is an under-estimated condition and is very likely the most frequent cause of dry eye disease. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. TearScience’s integrated, in-office system enables eye care professionals to effectively address a root cause of evaporative dry eye, obstructed Meibomian glands. For additional information, visit www.tearscience.com.
# # #